Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer

ATLANTA, Nov. 6, 2014 /PRNewswire/ -- Celtaxsys, Inc. is pleased to announce the appointment of Sanjeev Ahuja, MD, MBA, FACP as Chief Medical Officer, effective November 1, 2014.  Greg Duncan, President and CEO of Celtaxsys said, "On behalf of the board and the executive team, we are pleased to welcome Doctor Ahuja to Celtaxsys. Sanjeev brings to Celtaxsys a wonderful blend of global research capabilities, including designing and managing highly successful drug development programs, extensive regulatory authority engagement and first class key opinion leader development expertise.  His professional appointments include a diverse selection of organizations, ranging from big pharma to specialty pharma to biotech.  His record of achievement across a number of therapeutic areas make him a perfect choice to oversee the progression of our neutrophil modulation research programs in Cystic Fibrosis, Gout and Acne."

Sanjeev has over 30 years of experience as a physician including over 14 years in the pharmaceutical/biotechnology industry. He has training and clinical practice experience in obstetrics-gynecology and internal medicine. 

Since joining the industry in 2000 at Lilly, he has been involved in drug development across several therapeutic areas and in all phases of clinical development.  Sanjeev's industry experience spans large pharmaceutical companies and start-ups. He helped establish the R&D joint venture for Lilly in India, managed the R&D collaborations in immunology-inflammation for Sanofi Genzyme, and was most recently Chief Medical Officer at On Target Laboratories.  Sanjeev's medical degree is from the Armed Forces Medical College, Pune, India.

He is a Fellow of the American College of Physicians, and also has an MBA from the University of Cincinnati.

SOURCE Celtaxsys, Inc.

Related Links

http://www.celtaxsys.com